Tag: GlobeNewswire

Company Expects to Realize Approximately $600,000 in Annualized Cost Savings

SAN JOSE, Calif., Oct. 05, 2026 (GLOBE NEWSWIRE) — Iridex Corporation (Nasdaq: IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and accessories for the treatment of glaucoma and retinal diseases, today announced that it has completed the relocation of its manufacturing facility from Mountain View, California to a new facility in San Jose, California.

“We are pleased to announce the successful relocation of our manufacturing facility. This was a key component of our plan to reduce expenses and improve profitability,” said Patrick Mercer, President and CEO of Iridex. “This relocation is expected to improve operational efficiency while providing the infrastructure required to support the business we are building for the future.”

The completed relocation is set to generate approximately $0.6 million in annualized cost savings, consistent with the expectations outlined previously. The Company anticipates further savings opportunities as the transition is fully integrated into its operations.

About Iridex Corporation
Iridex Corporation is a worldwide leader in developing, manufacturing, and marketing innovative and versatile laser-based medical systems, which include capital equipment and consumable probes for the ophthalmology market. The Company’s proprietary MicroPulse^® technology delivers the therapeutic benefits of laser treatment while minimizing tissue damage, offering a safe, effective, and proven treatment for targeted sight-threatening eye conditions. Iridex’s current product line is used for the treatment of glaucoma and diabetic macular edema (DME) and other retinal diseases. Iridex products are sold in the United States through a direct sales force and internationally primarily through a network of independent distributors into more than 100 countries. For further information, visit the Iridex website at www.iridex.com.

Iridex, the Iridex logo, MicroPulse, the MicroPulse Logo, Iridex PASCAL, IQ 532, IQ 577, OcuLight, TxCell, Cyclo G6, MicroPulse P3, G-Probe, G-Probe Illuminate and EndoProbe are registered trademarks of Iridex Corporation, Inc. in the United States, Europe, and other jurisdictions.

Investor Relations Contact
Philip Taylor
Gilmartin Group
investors@iridex.com

TORONTO and GERMANTOWN, Md., Oct. 05, 2026 (GLOBE NEWSWIRE) — Sernova Biotherapeutics Inc. (“Sernova”) (TSX: SVA) (OTC: SEOVF) (FSE/XETRA: PSHO) and Seraxis Holdings, Inc. (“Seraxis”) today announced the closing of the previously announced targeted US$10 million non-brokered convertible note financing in connection with their proposed merger (the “Merger”) to form BetaNova Biotherapeutics, Inc. (“BetaNova”).

The US$11.2 million financing into Seraxis includes participation from insiders, Dr. Steven Sangha / Arlo Investments, Sernova management; Jonathan Rigby CEO, James Parsons CFO, Marylyn Rigby CCO, and David Burke VP IR, as well as Seraxis management; Will Rust Ph.D. CEO, and Carole Welsch Ph.D. COO. Existing shareholders and new investors also participated in the financing.

Proceeds from the financing are expected to support:

• cGMP manufacturing of SR-02, allogeneic stem cell-derived pancreatic islet cells;
• Enrollment of patients with T1D in Q4 for Phase 1 / 2 clinical trial;
• First patient dosing of SR-02 in Phase 1/2 clinical trial in Q1 2027 under an FDA-cleared IND with initial clinical data anticipated in H1 2027;
• Nasdaq listing readiness targeted for Q1 2027, subject to satisfaction of applicable listing requirements and approvals; and
• Advancement of SR-03, the next-generation gene-edited pancreatic islet cell program targeting immune evasion, toward an IND submission in the second half of 2027.

“This financing puts capital directly behind the milestones we have outlined for BetaNova as we passionately advance towards a potential functional cure for people living with T1D,” said Jonathan Rigby, President and Chief Executive Officer of Sernova. “With the financing now closed, we believe BetaNova is positioned to successfully compete with other companies in the T1D cell therapy space by entering the clinic in the near term. Our focus is on execution, while deploying capital efficiently.”

“Closing the financing provides the resources to advance the manufacturing activities required to support SR-02 islet cells and prepare for initiation of the Phase 1/2 clinical trial,” said Will Rust, Ph.D., President and Chief Executive Officer of Seraxis. “As we work toward completion of the Merger, our teams are aligned around a shared mission, a clear development strategy and a defined set of milestones for 2026 and 2027.”

Proposed Merger

Sernova and Seraxis entered into a definitive merger agreement on September 7, 2026, to form BetaNova, combining Seraxis’ stem cell-derived pancreatic islet programs and cGMP manufacturing capabilities with Sernova’s Cell Pouch Bio-hybrid Organ. The completion of the Merger is subject to required approvals and customary closing conditions. Upon completion, each of Sernova and Seraxis shareholders are expected to collectively own approximately 50% of BetaNova on a non-diluted basis.

Noble Capital Markets, Inc. is acting as exclusive financial advisor to Sernova in connection with the proposed Merger.

About the Financing

The US$11.2 million financing consists of convertible notes and common stock purchase warrants of Seraxis issued on a non-brokered basis. Upon completion of the Merger, the notes are expected to automatically convert into common stock of BetaNova.

ABOUT BETANOVA BIOTHERAPEUTICS, INC.

BetaNova Biotherapeutics, Inc. is the proposed combined company of Sernova Biotherapeutics Inc. and Seraxis Holdings, Inc. Subject to completion of the proposed transaction, BetaNova will be a clinical-stage regenerative medicine company focused on advancing cell-replacement therapies for type 1 diabetes. BetaNova will combine Seraxis’ stem cell-derived islet cell and cGMP manufacturing platform with Sernova’s Cell Pouch Bio-hybrid Organ.

ABOUT SERNOVA BIOTHERAPEUTICS INC.

Sernova Biotherapeutics Inc. is a clinical-stage company developing a regenerative medicine solution for T1D that combines its Cell Pouch implantation device, deep clinical experience in the engraftment of functional pancreatic cells, and therapeutic cells to create a Bio-hybrid, functional surrogate endocrine organ.

ABOUT SERAXIS HOLDINGS, INC.

Seraxis Holdings, Inc. develops stem cell-derived pancreatic islets under cGMP manufacturing processes. Seraxis’ mission is to demonstrate safety and potency of its islets in T1D patients without immune suppression therapy. To accomplish this goal, its lead allogeneic product, SR-02, is paired with an immune tolerizing strategy. Seraxis’ follow-on product SR-03 adds gene edits to SR-02 that increase compatibility with the host and potentially enhance long-term engraftment without immune suppression.

For Further Information Contact:

Investor Relations
David Burke
Vice President, Investor Relations
Sernova Biotherapeutics Inc.
(917) 751-5713
David.Burke@sernova.com

Media
Gloria Gasaatura
VP, LifeSci Communications
SernovaPR@lifescicomms.com

Forward-Looking Information

This news release contains “forward-looking statements” and “forward-looking information” within the meaning of applicable securities laws. Particularly statements and information regarding the proposed Merger of Sernova and Seraxis, the anticipated formation of BetaNova, the anticipated use of proceeds from the financing, manufacturing of SR-02, the timing of patient dosing and availability of clinical data, development of SR-03, and the anticipated completion of the Merger. In some cases, forward-looking information can be identified by the use of forward-looking terminology such as “plans”, “targets”, “expects” or “does not expect”, “is expected”, “an opportunity exists”, “budget”, “scheduled”, “estimates”, “outlook”, “forecasts”, “projection”, “prospects”, “strategy”, “intends”, “anticipates”, “does not anticipate”, “believes”, or variations of such words and phrases or statements that certain actions, events or results “may”, “could”, “would”, “might”, “will”, “will be taken”, “occur” or “be achieved”. In addition, any statements that refer to expectations, intentions, projections or other characterizations of future events or circumstances contain forward-looking information.

Statements containing forward-looking information are not historical facts but instead represent management’s expectations, estimates and projections regarding future events or circumstances. These statements include, without limitation, statements regarding the receipt, in a timely manner, of shareholder, court and regulatory approvals in respect of the Merger, the expected closing date for the Merger and BetaNova’s leadership, business prospects and operations following closing of the Merger and the anticipated use of proceeds and results thereof from the non-brokered financing. Undue reliance should not be placed on forward-looking information. The forward-looking information in this press release is based on our opinions, estimates and assumptions in light of our experience and perception of historical trends, current conditions and expected future developments, as well as other factors that we currently believe are appropriate and reasonable in the circumstances. Despite a careful process to prepare and review the forward-looking information, there can be no assurance that the underlying opinions, estimates and assumptions will prove to be correct. Further, forward-looking information is subject to known and unknown risks, uncertainties and other factors that may cause actual results, level of activity, performance or achievements to be materially different from those expressed or implied by such forward-looking information, including but not limited to risks relating to regulatory interactions, manufacturing, patient recruitment, clinical development, financing requirements, completion of the proposed Merger and satisfaction of applicable Nasdaq listing requirements.

Additional information about the risks and uncertainties of Sernova’s business and material risk factors or assumptions on which information contained in forward-looking information is based is provided in Sernova’s disclosure materials, including Sernova’s most recently filed news release, annual information form and any subsequently-filed interim management’s discussion and analysis, which are available under our profile on SEDAR+ at www.sedarplus.ca. There can be no assurance that such information will prove to be accurate, as actual results and future events could differ materially from those anticipated in such information. Accordingly, readers should not place undue reliance on forward-looking information, which speaks only as of the date made. The forward-looking information contained in this press release represents our expectations as of the date of this news release and is subject to change after such date. Sernova disclaims any intention or obligation or undertaking to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as required by applicable securities law.

Partnership intended to establish a Texas-based manufacturing pathway for pharmaceutical-grade ibogaine as TIRC advances its planned U.S. development program

HIGHLIGHTS

• Texas Ibogaine Research Corporation (“TIRC”), the wholly-owned Texas subsidiary of Psyence BioMed, enters manufacturing partnership with Benuvia Operations, LLC for the planned U.S. manufacture of pharmaceutical-grade ibogaine active pharmaceutical ingredient (“API”)
• Benuvia operates an 83,000-square-foot, DEA-registered controlled-substance manufacturing facility in Round Rock, Texas, with capabilities spanning development through commercial-scale production
• Partnership is intended to connect TIRC’s planned exclusive U.S. access to PsyLabs’ pharmaceutical-grade ibogaine under TIRC’s previously announced binding term sheet with PsyLabs, with U.S.-based controlled-substance manufacturing capabilities
• The partnership represents another step in Psyence BioMed’s strategy to build an integrated U.S. supply, manufacturing and regulatory development platform for ibogaine through TIRC

NEW YORK, Oct. 05, 2026 (GLOBE NEWSWIRE) — Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence BioMed” or the “Company”) today announced that its wholly-owned Texas subsidiary, Texas Ibogaine Research Corporation (“TIRC”), has entered into a manufacturing services agreement with Benuvia Operations, LLC (“Benuvia”) of Round Rock, Texas, establishing a manufacturing partnership for the planned U.S. manufacture of pharmaceutical-grade ibogaine active pharmaceutical ingredient (“API”) under current Good Manufacturing Practice (“cGMP”) standards.

The manufacturing partnership builds upon TIRC’s previously announced binding term sheet with Psyence Labs Ltd. (“PsyLabs”), a significant shareholder of Psyence BioMed and in which Psyence BioMed holds an ownership interest, for an exclusive U.S. license, supply and wholesale distribution arrangement covering PsyLabs’ pharmaceutical-grade ibogaine. The term sheet is to be superseded by a definitive agreement, which the parties have agreed to conclude on or before November 30, 2026. PsyLabs’ material is supported by a regulatory-readiness package that includes GMP-compliant production, an Investigator’s Brochure and certificates of analysis.

Benuvia operates an approximately 83,000-square-foot pharmaceutical manufacturing facility in Round Rock, Texas, registered with the U.S. Drug Enforcement Administration (“DEA”), with capabilities spanning controlled-substance API development and manufacturing, analytical development, stability programs and regulatory support. According to Benuvia, it currently holds approximately half of the U.S. aggregate production quota for ibogaine, providing an established foundation for potential domestic production. Applications for the import permit and procurement quota required for the planned production are being advanced with the DEA by Benuvia. Because Benuvia’s commercial-scale manufacturing infrastructure is already in place, the Company believes that the timing and scale of any U.S. ibogaine production will be governed primarily by applicable DEA quotas, controlled-substance import requirements and other regulatory authorizations.

“Benuvia brings a DEA-registered U.S. facility with the quota, systems and track record required to manufacture controlled substances to pharmaceutical standards,” said Jody Aufrichtig, Chief Executive Officer of Psyence BioMed and TIRC. “Combined with our planned licensed supply, we believe this has the potential to create an end-to-end pathway from pharmaceutical-grade source material through U.S.-based manufacturing.”

“Benuvia brings more than 10 years of experience in the development and commercial manufacturing of DEA Schedule I–V controlled substances to rigorous pharmaceutical standards,” said Terry Novak, Chief Executive Officer of Benuvia. “Our Round Rock facility was purpose-built for controlled-substance manufacturing and provides the infrastructure, regulatory capabilities, and commercial-scale capacity required for complex programs like ibogaine. While ibogaine has been discussed for decades, pharmaceutical-grade manufacturing capacity in the United States has remained extremely limited. Through our partnership with TIRC and Psyence BioMed, we believe we have an opportunity to change that — manufacturing ibogaine in America, to exacting specifications and at the scale this program will require if and as DEA quota expands. We have the experience, the facility, and the team in place. We are ready to begin.”

“For a regulated ibogaine development program, manufacturing is inseparable from the regulatory strategy,” said Dr. John Thorne, Project Lead, TIRC. “Establishing a U.S.-based manufacturing pathway is intended to strengthen chain-of-custody controls, batch consistency and the chemistry, manufacturing and controls work required to support future regulatory submissions. We believe Benuvia’s capabilities give us an experienced U.S. manufacturing platform on which to build that work.”

Psyence BioMed views this manufacturing partnership as more than a manufacturing milestone; it is part of a broader effort to advance the clinical and regulatory work required to develop potential ibogaine-based therapies for patients facing significant unmet needs, including opioid use disorder, other substance use disorders and mental health conditions affecting veterans.

The Company believes that the combination of pharmaceutical-grade supply at source and Texas-based cGMP manufacturing would position TIRC to support regulated research and clinical programs if and when applicable quotas are expanded. If compliant U.S. production capacity is established, the Company believes it would be better positioned to support the research and clinical development programs that could ultimately underpin future regulatory approvals and patient access.

ABOUT PSYENCE BIOMED

Psyence Biomedical Ltd. (Nasdaq: PBM) is a Nasdaq-listed company with its wholly-owned subsidiary, Texas Ibogaine Research Corporation, headquartered in Texas. It is one of the few multi-asset, vertically integrated biopharmaceutical companies specializing in neuroplastogen-based therapeutics and the manufacture of pharmaceutical-grade drug candidates. It is the first life sciences biotechnology company focused on developing nature-derived, non-synthetic psilocybin and ibogaine-based neuroplastogen medicine to be listed on Nasdaq. The Company is dedicated to addressing unmet mental health needs and is committed to an evidence-based approach to developing safe, effective and FDA-approved nature-derived neuroplastogen treatments across a range of mental health disorders.

ABOUT PSYLABS

PsyLabs is a neuroplastogen active pharmaceutical ingredient development company, federally licensed in its operating jurisdiction to cultivate, extract and export psilocybin mushrooms and other neuroplastogen compounds, including psilocybin, psilocin, mescaline, ibogaine and dimethyltryptamine, to lawful medical and research markets. PsyLabs operates from an ISO 22000 and GMP-compliant facility, with a focus on natural compound purification, regulatory support and global distribution. www.psylabs.life

CONTACTS

Psyence Biomedical Ltd. · ir@psyencebiomed.com · media@psyencebiomed.com · info@psyencebiomed.com · +1 416-477-1708

Investor contact: Michael Kydd, Investor Relations Advisor — michael@psyencebiomed.com

FORWARD-LOOKING STATEMENTS

This communication contains “forward-looking statements” within the meaning of applicable securities laws, including the U.S. Private Securities Litigation Reform Act of 1995. These include statements regarding the manufacturing partnership with Benuvia and its intended scope, benefits and timing; the planned U.S. manufacture of pharmaceutical-grade ibogaine API; the timing and outcome of import permit, procurement quota and other DEA applications and authorizations; the ability to manufacture material to specification and on schedule; the potential for future increases in DEA quotas; the conclusion of a definitive agreement with PsyLabs in accordance with the previously announced binding term sheet and the rights to be granted to TIRC under it; the Company’s strategy to build an integrated U.S. supply, manufacturing and regulatory development platform for ibogaine through TIRC; the planned U.S. development program and any future clinical, regulatory or commercial activities; and the Company’s ability to support regulated research and clinical programs. Forward-looking statements may be identified by words such as “will,” “expects,” “intends,” “plans,” “anticipates,” “believes,” “estimates” and similar expressions.

These statements are based on assumptions regarding government policy, continued interest in regulated neuroplastogen research, the availability of lawful development pathways, and the Company’s ability to maintain licenses, permits, supply arrangements and third-party relationships. These assumptions may prove incorrect. Risks and uncertainties that could cause actual results to differ materially include that import permit, quota, registration or other regulatory approvals are delayed, limited or refused; that the arrangements with Benuvia are terminated, are not performed or do not proceed as intended; reliance on a single manufacturing partner and the consequences of any interruption; manufacturing, analytical or supply-chain failures; that a definitive agreement with PsyLabs is not concluded by November 30, 2026, or at all, or is concluded on terms that differ from the term sheet; dependence on PsyLabs, a related party, as exclusive licensor and supplier; changes in law, regulation or enforcement priorities in the United States or elsewhere; the continuing status of ibogaine as a controlled substance; clinical, regulatory and approval risks; financing risk; and the Company’s ability to maintain compliance with Nasdaq continued listing standards. This list is not exhaustive. These risks should be considered together with the risk factors described in the “Risk Factors” section of the Company’s Annual Report on Form 20-F for the fiscal year ended March 31, 2026 and in the Company’s other filings with the U.S. Securities and Exchange Commission. Nothing in this communication should be regarded as a representation by any person that the forward-looking statements set forth herein will be achieved or that any of the contemplated results of such forward-looking statements will be achieved. Readers should not place undue reliance on forward-looking statements, which speak only as of the date made. Except as required by law, the Company undertakes no obligation to update such statements.

The Company makes no medical, treatment or health benefit claims regarding its proposed products. The U.S. Food and Drug Administration, Health Canada and other regulatory authorities have not approved ibogaine or the Company’s other neuroplastogen compounds for therapeutic use, and their safety and efficacy have not been established through authorized clinical research. Rigorous scientific research and clinical trials are required. Information in this communication regarding Benuvia, including its facility, capabilities, DEA registration and quota allocations, has been provided by Benuvia and has not been independently verified by the Company. Any references to ibogaine stock, inventory or doses are the Company’s best estimates only. References to GMP-compliant mean production in a facility designed, operated and controlled in accordance with applicable Good Manufacturing Practice standards, and do not themselves constitute a representation of formal certification or approval by any regulatory authority unless expressly stated. References to a planned clinical trial describe an activity under evaluation only; no trial has been commenced, and no regulatory application in respect of it has been filed or accepted.

This communication is not an offer to sell or a solicitation of an offer to buy any securities.

Alector grants Genentech exclusive rights to develop and commercialize AL050, an investigational GCase Enzyme Replacement Therapy (ERT) enabled by Alector Brain Carrier (ABC), Alector’s proprietary blood-brain barrier delivery platform

Alector to receive $100 million upfront payment, with potential for up to $1.17 billion in additional milestone payments, as well as tiered royalties on net sales

SOUTH SAN FRANCISCO, Calif., Oct. 05, 2026 (GLOBE NEWSWIRE) — Alector, Inc. (Nasdaq: ALEC), a biotechnology company focused on developing therapies to counteract the devastating progression of neurodegeneration, today announced it has entered into an exclusive global licensing agreement with Genentech, a member of the Roche Group, granting Genentech worldwide rights to develop and commercialize Alector’s AL050 program, its brain-penetrant engineered glucocerebrosidase (GCase) ERT.

AL050 is designed to address GCase deficiency, a driver of neurodegeneration in Parkinson’s Disease that is most pronounced in – but not limited to – carriers of GBA1 mutations. It combines an Alector-engineered GCase, optimized for greater enzymatic activity and a longer half-life, with Alector’s ABC, which is designed to transport therapeutics across the blood-brain barrier. Delivered into the brain, the enzyme is intended to break down glucosylsphingosine and glucosylceramide, lipids that accumulate in neurons and other brain cells upon GCase deficiency and contribute to neurodegeneration, with the aim of reducing cellular dysfunction and slowing disease progression.

“Deficient GCase activity is increasingly recognized as a contributor to Parkinson’s Disease, and there is still no approved therapy that addresses the underlying enzyme deficiency,” said Arnon Rosenthal, Ph.D., Chief Executive Officer of Alector. “The challenge in treating GCase deficiency is twofold: engineering an enzyme with optimal activity and durability and successfully delivering it to the brain. AL050 addresses this by pairing an engineered GCase enzyme with our proprietary Alector Brain Carrier technology designed to cross the blood-brain barrier. Genentech’s long-standing commitment to Parkinson’s Disease makes them an ideal partner as this program moves toward the clinic”.

“Parkinson’s Disease is one of the fastest-growing neurological conditions worldwide,” said Boris L. Zaïtra, Head of Roche Corporate Business Development. “By partnering with companies such as Alector we aim to delay or halt the progression of Parkinson’s so patients maintain and prolong their independence.”

Under the terms of the agreement, Alector will receive an upfront payment of $100 million and is also eligible to receive additional payments of up to $1.17 billion upon the achievement of development, regulatory, and commercial milestones. Alector is also eligible for tiered royalties on net sales. Under the collaboration, Genentech will be responsible for development, regulatory, manufacturing, and commercialization across all indications.  Alector retains ownership of ABC and full rights to apply the platform across its wholly owned pipeline.  

“This partnership extends our cash runway into 2029, providing resources to advance our fully active, subcutaneously delivered, brain-enabled anti-Aβ antibody to multi-cohort clinical data in Alzheimer’s patients, and move our subcutaneously delivered, brain-enabled Tau siRNA and alpha- synuclein siRNA programs through IND-enabling studies and to IND filings,” said Dr. Rosenthal.

Alector R&D Webinar on Wholly Owned Pipeline

Alector will host a scientific webinar on Tuesday, October 13^th, 2026, at 8:00 a.m. PT, focused on AL137, its brain-enabled anti-Aβ antibody; AL164, its tau siRNA program; and AL062, its alpha-synuclein siRNA program. Registration and webcast information will be available on the Events and Presentations page of the Alector corporate website.

About Alector

Alector is a biotechnology company focused on developing therapies to counteract the devastating progression of neurodegenerative diseases. Leveraging the principles of genetics, immunology, and neuroscience, the company is advancing a portfolio of programs that aim to remove toxic proteins, replace missing proteins, and restore immune and nerve cell function. Supported by biomarkers, Alector’s product candidates seek to treat a range of indications, such as Alzheimer’s disease and Parkinson’s disease. The company is also developing Alector Brain Carrier (ABC), a proprietary blood-brain barrier platform, which is being applied to its preclinical and research pipeline. ABC aims to enhance the delivery of therapeutics, achieve deeper brain penetration and efficacy at lower doses, and ultimately improve patient outcomes while reducing costs. Alector is headquartered in South San Francisco, California. For more information, please visit www.alector.com.

Forward Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release include, but are not limited to, statements regarding our business plans, business strategy, product candidates, research and preclinical pipeline, blood-brain barrier technology platform, planned and ongoing preclinical studies, planned clinical trials, expected milestones, expectations of our collaborations, and financial and cash guidance. Such statements are subject to numerous risks and uncertainties, including but not limited to risks and uncertainties as set forth in Alector’s Annual Reports on Form 10-K and Quarterly Reports on Form 10-Q, with the Securities and Exchange Commission (SEC), as well as the other documents Alector files from time to time with the SEC. These documents contain and identify important factors that could cause the actual results for Alector to differ materially from those contained in Alector’s forward-looking statements. Any forward-looking statements contained in this press release speak only as of the date hereof, and Alector specifically disclaims any obligation to update any forward-looking statement, except as required by law.

Alector Contacts

Argot Partners (media)
David Rosen
646-461-6387
alector@argotpartners.com

Argot Partners (investors)
Laura Perry
alector@argotpartners.com

—Supports BioCryst’s evolution toward a more disciplined R&D model centered on external innovation—

RESEARCH TRIANGLE PARK, N.C., Oct. 05, 2026 (GLOBE NEWSWIRE) — BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced the formation of a Scientific Advisory Board (SAB) comprising seven accomplished scientific and industry leaders with deep expertise across rare disease research and drug development. The SAB will provide independent scientific and strategic guidance as the Company advances its research and development strategy and builds a high value novel drug pipeline.

“The formation of BioCryst’s Scientific Advisory Board marks an important step in the evolution of our new R&D model,” said Dr. Sandeep Menon, BioCryst’s Chief Research and Development Officer. “External innovation is increasingly central to how we build our pipeline, and guidance from leading scientists and physicians will sharpen our thinking and strengthen the diligence behind each program we evaluate and advance. The Scientific Advisory Board will work closely with me and our Chief Scientific Officer, Dr. David Jenkins, as we shape and execute BioCryst’s R&D strategy.”

“Building on our success in developing and commercializing medicines for hereditary angioedema, we are bringing the same rigor to the next generation of BioCryst medicines,” said Charlie Gayer, Chief Executive Officer. “With the expertise of these highly experienced scientific advisors, BioCryst will be better positioned to evaluate emerging opportunities and translate their potential into meaningful benefits for patients.”

The SAB will provide strategic guidance across BioCryst’s research and development activities, including pipeline expansion, external innovation opportunities, translational science and clinical development. The board will also offer insights on regulatory strategy and help strengthen connections with leading scientific, medical and patient communities worldwide.

“Few companies have demonstrated BioCryst’s ability to translate rigorous science into rare disease medicines that reach patients, and that track record is what makes the Company’s evolution so compelling,” said Dr. Anthony Manning, Chair of the Scientific Advisory Board. “The formation of this Board is an important step for BioCryst, and it is a privilege to chair a group with this depth of experience across rare disease drug discovery, translational science and clinical development. I am confident the Company’s decisions about which science to pursue and how to advance it will benefit from the collective judgment of its members.”

Scientific Advisory Board Members:

• Anthony (Tony) Manning, PhD, Chair, is Principal at Manning Bio Worldwide, LLC, advising biotechnology companies and academic institutions following a 30-year career in pharmaceutical drug discovery and development. As Chief Scientific Officer at Momenta Pharmaceuticals (now part of Johnson & Johnson), he built a pipeline of first-in-class therapeutics for rare autoantibody-driven diseases, including nipocalimab (IMAAVY), now FDA-approved for generalized myasthenia gravis and warm autoimmune hemolytic anemia, with additional indications in development. Earlier, he led drug discovery efforts at Roche Pharmaceuticals and Biogen Idec, contributing to the approvals of Actemra and Rituxan, and to the development of litifilimab, now in Phase 3 for lupus.
   
• Dr. Christine Bulawa, PhD, received a PhD from the University of Wisconsin-Madison and completed postdoctoral studies at Massachusetts Institute of Technology (MIT). As part of her 20+ years in rare disease drug discovery, she was the first employee of FoldRx Pharmaceuticals and instrumental in the preclinical development of tafamidis, the first pharmacological treatment for transthyretin amyloidosis. As a senior leader in Pfizer’s Rare Disease Research Unit, Dr. Bulawa built a pipeline of innovative programs based on rigorously validated targets, spanning portfolio entry to clinical development, with a focus on small molecule and genetic therapies to treat degenerative neurological, neuromuscular and protein aggregation diseases. 
   
• Dr. Eric A. Hughes, MD, PhD, serves as Executive Vice President, Global Research & Development and Chief Medical Officer at Teva Pharmaceuticals. A physician-scientist who earned his MD and PhD from Yale University, Dr. Hughes brings nearly 20 years of biopharmaceutical industry experience and is helping advance Teva’s transformation into a leading innovative biopharmaceutical company, enabled by a world-class generics business.  Prior to Teva, he served in leadership roles at Vertex, Novartis and Bristol Myers Squibb.
   
• Dr. Stephanie Noviello, MD, MPH, is Chief Medical Officer at ILiAD Biotechnologies, Inc. She is a clinical development leader with extensive experience across infectious diseases, virology, immunology, rare diseases and skeletal diseases at Novartis, Motif BioSciences, Bristol-Myers Squibb and Schering-Plough Research Institute.
   
• Dr. Shashi Ramaiah, DVM, PhD, DACVP, DABT, is a board-certified Veterinary Pathologist and Toxicologist who spent 18 years at Pfizer, most recently as Vice President and Global Head of Discovery, Investigative and Translational Sciences. He is Founder and CEO of SPECCRO, a drug development advisory firm that helps biotechnology companies and investors de-risk programs and portfolios, drawing on more than 40 senior industry experts and extensive engagement with national and international scientific consortia.
   
• Dr. Art Taveras, PhD, is a seasoned biopharmaceutical executive with over 35 years of industry experience, specializing in leading R&D divisions across major public pharmaceutical corporations and biotech firms including Biogen Idec, Transform Therapeutics, X4 Pharmaceuticals, CoMET Therapeutics, ShangPharma ChemPartner, Alantos Pharmaceuticals and Schering-Plough. His strategic expertise as President, CEO, CSO and R&D Leader has advanced robust pipelines and key global R&D partnerships, culminating in over 175 patent application filings, 150 publications, 60 clinical trials, 6 regulatory agency approvals and 5 therapeutic platform technologies across commercial and clinical-stage assets for diseases in neurology, oncology, immunology, metabolism and rare disease.
   
• Dr. Ajay Yekkirala, PhD, is an experienced serial entrepreneur who co-founded Superluminal Medicines at RA Capital and built a strong investor syndicate including NVIDIA, Eli Lilly, Insight Partners, Catalio, BVF and Perceptive Advisors. As Chief Scientific Officer, he directs the AI/ML platform build and all pipeline R&D. Prior to Superluminal, Dr. Yekkirala founded Blue Therapeutics to develop non-addictive painkillers. He received his PhD from the University of Minnesota and completed postdoctoral training at Harvard Medical School. He has authored several papers published in high-impact, peer-reviewed journals and advised various committees at the NIH, including EPPIC-NET at NINDS and Medication Development Research Committee at NIDA.

About BioCryst Pharmaceuticals
BioCryst is a global biotechnology company focused on developing and commercializing medicines for hereditary angioedema (HAE) and other rare diseases, driven by its deep commitment to improving the lives of people living with these conditions. BioCryst has commercialized ORLADEYO® (berotralstat), the first oral, once-daily plasma kallikrein inhibitor and is advancing a pipeline of potential first-in-class or best-in-class therapeutics for rare diseases. For more information, please visit www.biocryst.com or follow us on LinkedIn.

Forward-Looking Statements

This press release contains forward-looking statements, including statements regarding future results, performance, or achievements, expectations regarding BioCryst’s strategic shift to prioritize external innovation, expectations regarding pipeline development, the anticipated role and potential benefits of BioCryst’s Scientific Advisory Board, and statements related to BioCryst’s future operations, prospects and pipeline programs. These statements involve known and unknown risks, uncertainties and other factors which may cause BioCryst’s actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. These statements reflect our current views with respect to future events and are based on assumptions and are subject to risks and uncertainties. Given these uncertainties, you should not place undue reliance on these forward-looking statements. Some of the factors that could affect the forward-looking statements contained herein include: BioCryst’s ability to successfully progress its pipeline development plans; guidance and recommendations provided by the Scientific Advisory Board may not improve BioCryst’s evaluation or advancement of potential programs or result in the anticipated benefits; the commercial viability of BioCryst’s future rare disease therapies; ongoing and future development of product candidates may take longer than expected and may not have positive results; product candidates, if approved, may not achieve market acceptance; the results of BioCryst’s partnerships with third parties may not meet BioCryst’s current expectations; and BioCryst’s ability to realize the contemplated benefits of its new R&D strategy and model and successfully evaluate and execute external opportunities. This list is not exclusive. To see a more comprehensive list of risks, please refer to the documents BioCryst files periodically with the Securities and Exchange Commission, specifically BioCryst’s most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and Current Reports on Form 8-K, which identify important factors that could cause actual results to differ materially from those contained in BioCryst’s projections and forward-looking statements.

Contact:

Investors:
investorrelations@biocryst.com

Media:
media@biocryst.com

DV helps advertisers measure the impact of advertising in ChatGPT across the customer journey while developing brand risk and suitability pilots for conversational advertising

NEW YORK, Oct. 05, 2026 (GLOBE NEWSWIRE) — DoubleVerify (“DV”) (NYSE: DV), the leading software platform to verify media quality, optimize advertising performance and prove campaign outcomes, today announced the launch of attribution measurement for advertising on ChatGPT. Advertisers can now incorporate ChatGPT Ads as a touchpoint within the broader customer journey, helping them understand its contribution to outcomes and overall return on ad spend (ROAS).

DV and OpenAI are also developing a brand suitability evaluation pilot designed to enable independent partners to collaborate with OpenAI to assess and help inform brand suitability policies and guardrails in a controlled testing environment, without accessing private user conversations.

Understanding ChatGPT Ads’ Role in the Customer Journey

With this announcement, DV enables advertisers to measure ChatGPT Ads alongside their other marketing touchpoints, helping brands understand how the channel contributes to acquisition goals, conversions and overall campaign performance. By incorporating ChatGPT Ads into their attribution measurement, advertisers can evaluate its impact alongside other channels rather than viewing performance in isolation.

“Advertisers want to understand not just whether a new channel is performing, but the business impact it’s actually driving,” said Mark Zagorski, CEO of DV. “By bringing ChatGPT Ads into DV’s attribution measurement through DV Rockerbox™, marketers can connect engagement on ChatGPT to outcomes and return on ad spend, giving them a clearer view of its role across the customer journey.”

Early results demonstrate the value of this approach. Weight Watchers added ChatGPT Ads as a new source of member acquisition and used DV Rockerbox to independently measure its performance. ChatGPT’s attributed cost per acquisition was 15.3% below Weight Watchers’ established benchmark during the measured period, providing an early signal of the channel’s potential as the company evaluates increased investment.

“As new advertising channels emerge, we need to understand how they contribute to the broader customer journey,” said Jake Dmochowski, VP of Growth, Weight Watchers. “DV Rockerbox helped us put ChatGPT Ads performance into context alongside our existing investments, giving us an encouraging early signal and greater clarity as we evaluate how to scale.”

Advancing Brand Suitability for ChatGPT Ads

As part of this announcement, DV and OpenAI are developing a brand risk and suitability evaluation pilot designed to assess conversational context at scale, helping advertisers determine whether ad placements align with their brand suitability preferences. The goal is to give advertisers greater transparency into how those policies and guardrails work while protecting conversation privacy.

“Conversational environments are fundamentally different because context is dynamic. What a user asks, how the AI responds and how the conversation evolves can all shape the environment in which an ad appears,” added Zagorski. “That requires a new approach to brand risk and suitability. As advertising on ChatGPT scales, advertisers need confidence that their brands are appearing in suitable environments, with context evaluated while user privacy is protected.”

Together, attribution and brand suitability measurement will address two fundamental advertiser needs: understanding the business impact of their investment and gaining greater confidence in the context in which their brands appear.

DV’s brand suitability and attribution capabilities are part of the DV Media AdVantage Platform (DV MAP™), the full-spectrum media effectiveness platform that combines media verification, AI-powered optimization through DV Scibids AI™ and campaign outcomes measurement with DV Rockerbox to maximize media effectiveness and return on ad spend. These capabilities help advertisers drive stronger business outcomes across channels, devices and formats.

For more information about this release, contact Sales@doubleverify.com

About DV

DoubleVerify (“DV”) (NYSE: DV) is the industry’s leading media effectiveness platform that leverages AI to drive superior outcomes for global brands. By powering media efficiency and performance, DV strengthens the online advertising ecosystem, preserving the fair value exchange between buyers and sellers of digital media. Learn more at www.doubleverify.com

Chris Harihar 
646-535-9475 
chris@crenshawcomm.com 

LAFAYETTE, Ind., Oct. 05, 2026 (GLOBE NEWSWIRE) — Wabash (NYSE: WNC) today announced that it will webcast its quarterly earnings conference call to review and discuss its financial results for the third quarter of 2026 on Thursday, October 29, 2026, beginning at 12:00 p.m. ET.

The call and an accompanying slide presentation will be accessible on the “Investors” section of Wabash’s website, www.onewabash.com, under “Events & Presentations.” The conference call will be accessible at the following link: https://events.q4inc.com/attendee/756116794 replay of the call will be available shortly after the conclusion of the presentation. Access to the replay will be available on the “Investors” section of Wabash’s website under “Events & Presentations.”

Wabash’s earnings press release, earnings slides and any other related presentation materials will be posted to the “Investors” section of Wabash’s website by 7:00 a.m. ET on the date of the earnings call and will remain available following the call.

Wabash: Changing How the World Reaches You 
Wabash (NYSE: WNC) combines physical and digital technologies to deliver innovative, end-to-end solutions that optimize supply chains across transportation, logistics and infrastructure markets. Headquartered in Lafayette, Indiana, Wabash designs, manufactures, and services an extensive range of products supporting first-to-final mile operations, including dry and refrigerated trailers and truck bodies, platform trailers, tank trailers, structural composites and more. In addition, through the Wabash Marketplace and Wabash Parts, customers gain access to a nationwide parts and service network, Trailers as a Service (TaaS)℠, and advanced tools designed to streamline operations and drive growth. By enabling businesses to thrive today and prepare for tomorrow, Wabash is Changing How the World Reaches You^®. Learn more at onewabash.com.

Media Contact:
Heidi Murphy
Heidi.murphy@padillaco.com

Investor Relations:
John Cummings
Sr. Director, FP&A & IR
(765) 262-2898
john.cummings@onewabash.com

Findings highlight opportunities for further improvement in treatment use and adherence, despite the availability of multiple long-term prophylaxis and on-demand treatment options

ZUG, Switzerland, Oct. 05, 2026 (GLOBE NEWSWIRE) — Pharvaris (Nasdaq: PHVS) a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs of those living with bradykinin-mediated angioedema (AE-BK), such as hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH), today announced that insights from a Pharvaris-funded analysis of the multinational Adelphi Real World HAE Disease Specific Programme™ (DSP) dataset evaluating how HAE is managed in clinical practice have been published in Advances in Therapy.

The analysis evaluated real-world patterns of HAE disease management including frequency, severity, and characteristics of HAE attacks; use of long-term prophylaxis (LTP) and on-demand treatment (ODT); patient and physician decision-making around treating or not treating attacks; treatment adherence and reasons for suboptimal adherence; and patient and physician perspectives on treatment satisfaction and unmet needs.

“By incorporating both physician-reported clinical data and patient-reported experiences, this analysis provides a comprehensive view of how hereditary angioedema is managed in routine clinical practice,” said Peng Lu, M.D., Ph.D., President of Pharvaris. “Early diagnosis and effective treatment remain critical, yet this real-world analysis highlights remaining gaps between guideline-recommended care and the actual experience of people with HAE. Addressing these gaps may help improve treatment outcomes, enhance patient satisfaction, and optimize overall disease management. These findings highlight the importance of understanding how treatment decisions are made in real-world settings and the barriers that may still limit alignment with clinical guidelines. At Pharvaris, we are committed to supporting the HAE community by leveraging insights to inform decisions and to identify solutions that may further inform medical care and address the practical and clinical needs of patients and physicians in everyday practice.”

Study Insights
The analysis identified gaps that currently persist between guideline-recommended care and real-world practice. Patient satisfaction with treatment and the decision to change treatment were mostly driven by ease of portability, route of administration, perceived efficacy, and the odds of experiencing adverse events. In addition, treatment burden—particularly related to route of administration, convenience, and integration into daily life—continues to impact patient behavior and satisfaction.

With regards to on-demand treatment of attacks, a substantial proportion of patients do not treat all HAE attacks, most commonly because attacks are perceived as not severe enough to use treatments patients perceive being associated with increased burden. Other reasons included the lack of availability of therapy and pain associated with injectable treatments. With regards to LTP treatment satisfaction, daily oral treatment was preferred over biweekly or monthly injections. These findings highlight ongoing unmet needs and suggest that real-world factors, including patient preferences and treatment usability, play a critical role in treatment outcomes.

Study Details
The analysis used data from the Adelphi Real World HAE DSP, a cross-sectional, retrospective survey conducted between January 2023 and January 2024 across the United States, Europe, and Japan. The study included 225 physicians, who completed record-based assessments for 1,131 patients with HAE, as well as 279 patients who provided direct, self-reported insights through questionnaires. This dual approach enabled comparison of physician-reported clinical data with patient-reported experiences, offering a comprehensive view of real-world HAE management. The survey captured both clinical characteristics and patient perspectives, including treatment behaviors and quality-of-life impact. Although the HAE treatment landscape has evolved between the time of the survey and present, the findings from the study are still considered actual.

The full publication can be found here: https://link.springer.com/article/10.1007/s12325-026-03790-2

About Pharvaris
Pharvaris is a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs in bradykinin-mediated conditions, including all types of bradykinin-mediated angioedema. Pharvaris’ aspiration is to offer therapies with injectable-like efficacy™, a well-tolerated profile, and the convenience of oral administration to prevent and treat bradykinin-mediated angioedema attacks. By delivering on this aspiration, Pharvaris aims to provide a new standard of care in bradykinin-mediated angioedema. For more information, visit https://pharvaris.com/.

Forward-Looking Statements
This press release contains certain forward-looking statements that involve substantial risks and uncertainties. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including, without limitation, statements relating to our future plans, studies and trials, and any statements containing the words “believe,” “anticipate,” “expect,” “estimate,” “may,” “could,” “should,” “would,” “will” and similar expressions. These forward-looking statements are based on management’s current expectations, are neither promises nor guarantees, and involve known and unknown risks, uncertainties and other important factors that may cause Pharvaris’ actual results, performance or achievements to be materially different from its expectations expressed or implied by the forward-looking statements. Such risks include but are not limited to the following: uncertainty in the outcome of our interactions with regulatory authorities, including the FDA; the expected timing, progress, or success of our clinical development programs, especially for deucrictibant immediate-release capsules and deucrictibant extended-release tablets, which are in late-stage global clinical trials; the outcome of regulatory approvals, including the outcome of our NDA and MAA for the on-demand treatment of acute attacks of HAE; our ability to replicate the efficacy and safety demonstrated in the RAPIDe-1, RAPIDe-2, RAPIDe-3, CHAPTER-1, and CHAPTER-3 Phase 2 and Phase 3 studies in ongoing and future nonclinical studies and clinical trials, such as CREAATE; risks arising from epidemic diseases, which may adversely impact our business, nonclinical studies, and clinical trials; our ability to potentially use deucrictibant for alternative purposes, for example to treat C1-INH deficiency (AAE-C1INH); the value of our ordinary shares; the timing, costs and other limitations involved in obtaining regulatory approval for our product candidates, or any other product candidate that we may develop in the future; our ability to establish commercial capabilities or enter into agreements with third parties to market, sell, and distribute our product candidates; our ability to compete in the pharmaceutical industry, including with respect to existing therapies, emerging potentially competitive therapies and with competitive generic products; our ability to market, commercialize and achieve market acceptance for our product candidates; our ability to produce sufficient amounts of drug product candidates for commercialization; our ability to raise capital when needed and on acceptable terms; regulatory developments in the United States, the European Union and other jurisdictions; our ability to protect our intellectual property and know-how and operate our business without infringing the intellectual property rights or regulatory exclusivity of others; our ability to manage negative consequences from changes in applicable laws and regulations, including tax laws (including the Biosecure Act), our ability to maintain an effective system of internal control over financial reporting; changes and uncertainty in general market conditions; disruptions at the FDA and other agencies; changes and uncertainty in general market, political and economic conditions, including as a result of inflation and geopolitical conflicts; changes in regulations and customs, tariffs and trade barriers; and the other factors described under the headings “Cautionary Statement Regarding Forward-Looking Statements” and “Item 3. Key Information—D. Risk Factors” in our Annual Report on Form 20-F and other periodic filings with the U.S. Securities and Exchange Commission. These and other important factors could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management’s estimates as of the date of this press release. New risks and uncertainties may emerge from time to time, and it is not possible to predict all risks and uncertainties. While Pharvaris may elect to update such forward-looking statements at some point in the future, Pharvaris disclaims any obligation to do so, even if subsequent events cause its views to change. These forward-looking statements should not be relied upon as representing Pharvaris’ views as of any date subsequent to the date of this press release.

CONTACT: Contact
Maggie Beller
Vice President, Head of Corporate and Investor Communications
maggie.beller@pharvaris.com

FORM 8.5 (EPT/RI)

PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY
Rule 8.5 of the Takeover Code (the “Code”)

1.        KEY INFORMATION

(a)        Name of exempt principal trader:	Investec Bank plc
(b)        Name of offeror/offeree in relation to whose relevant securities this form relates:         Use a separate form for each offeror/offeree	Pollen Street Group Limited
(c)        Name of the party to the offer with which exempt principal trader is connected:	Investec is Joint Broker to Pollen Street Group Limited
(d)        Date dealing undertaken:	02nd October 2026
(e)        In addition to the company in 1(b) above, is the exempt principal trader making disclosures in respect of any other party to this offer?         If it is a cash offer or possible cash offer, state “N/A”	N/A

2.        DEALINGS BY THE EXEMPT PRINCIPAL TRADER

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(b), copy table 2(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

The currency of all prices and other monetary amounts should be stated.

(a)        Purchases and sales

Class of relevant security	Purchases/ sales	Total number of securities	Highest price per unit paid/received	Lowest price per unit paid/received
Ordinary shares	Purchases	879	906	904
Ordinary shares	Sales	5000	911	900

(b)        Cash-settled derivative transactions

Class of relevant security	Product description e.g. CFD	Nature of dealing e.g. opening/closing a long/short position, increasing/reducing a long/short position	Number of reference securities	Price per unit
N/A	N/A	N/A	N/A	N/A

(c)        Stock-settled derivative transactions (including options)

(i)        Writing, selling, purchasing or varying

Class of relevant security	Product description e.g. call option	Writing, purchasing, selling, varying etc.	Number of securities to which option relates	Exercise price per unit	Type e.g. American, European etc.	Expiry date	Option money paid/ received per unit
N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

(ii)        Exercise

Class of relevant security	Product description e.g. call option	Exercising/ exercised against	Number of securities	Exercise price per unit
N/A	N/A	N/A	N/A	N/A

(d)        Other dealings (including subscribing for new securities)

Class of relevant security	Nature of dealing e.g. subscription, conversion	Details	Price per unit (if applicable)
N/A	N/A	N/A	N/A

3.        OTHER INFORMATION
        
(a)        Indemnity and other dealing arrangements

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the exempt principal trader making the disclosure and any party to the offer or any person acting in concert with a party to the offer: Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state “none”

None

(b)        Agreements, arrangements or understandings relating to options or derivatives

Details of any agreement, arrangement or understanding, formal or informal, between the exempt principal trader making the disclosure and any other person relating to: (i)        the voting rights of any relevant securities under any option; or (ii)        the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced: If there are no such agreements, arrangements or understandings, state “none”

None

Date of disclosure:	05th October 2026
Contact name:	Abhishek Gawde
Telephone number:	+91-9923757332

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.

The Panel’s Market Surveillance Unit is available for consultation in relation to the Code’s dealing disclosure requirements on +44 (0)20 7638 0129.

The Code can be viewed on the Panel’s website at www.thetakeoverpanel.org.uk.

FORM 8.5 (EPT/RI)

PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY
Rule 8.5 of the Takeover Code (the “Code”)

1.        KEY INFORMATION

(a)        Name of exempt principal trader:	Investec Bank Plc
(b)        Name of offeror/offeree in relation to whose relevant securities this form relates:         Use a separate form for each offeror/offeree	SThree Plc
(c)        Name of the party to the offer with which exempt principal trader is connected:	Investec is Joint Broker to SThree Plc
(d)        Date dealing undertaken:	02nd October 2026
(e)        In addition to the company in 1(b) above, is the exempt principal trader making disclosures in respect of any other party to this offer?         If it is a cash offer or possible cash offer, state “N/A”	N/A

2.        DEALINGS BY THE EXEMPT PRINCIPAL TRADER

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(b), copy table 2(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

The currency of all prices and other monetary amounts should be stated.

(a)        Purchases and sales

Class of relevant security	Purchases/ sales	Total number of securities	Highest price per unit paid/received	Lowest price per unit paid/received
Ordinary shares	Purchase	5,000	300	300
Ordinary shares	Sales	105	300.25	300

(b)        Cash-settled derivative transactions

Class of relevant security	Product description e.g. CFD	Nature of dealing e.g. opening/closing a long/short position, increasing/reducing a long/short position	Number of reference securities	Price per unit
N/A	N/A	N/A	N/A	N/A

(c)        Stock-settled derivative transactions (including options)

(i)        Writing, selling, purchasing or varying

Class of relevant security	Product description e.g. call option	Writing, purchasing, selling, varying etc.	Number of securities to which option relates	Exercise price per unit	Type e.g. American, European etc.	Expiry date	Option money paid/ received per unit
N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

(ii)        Exercise

Class of relevant security	Product description e.g. call option	Exercising/ exercised against	Number of securities	Exercise price per unit
N/A	N/A	N/A	N/A	N/A

(d)        Other dealings (including subscribing for new securities)

Class of relevant security	Nature of dealing e.g. subscription, conversion	Details	Price per unit (if applicable)
N/A	N/A	N/A	N/A

3.        OTHER INFORMATION

(a)        Indemnity and other dealing arrangements

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the exempt principal trader making the disclosure and any party to the offer or any person acting in concert with a party to the offer: Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state “none”

None

(b)        Agreements, arrangements or understandings relating to options or derivatives

Details of any agreement, arrangement or understanding, formal or informal, between the exempt principal trader making the disclosure and any other person relating to: (i)        the voting rights of any relevant securities under any option; or (ii)        the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced: If there are no such agreements, arrangements or understandings, state “none”

None

Date of disclosure:	05th October 2026
Contact name:	Abhishek Gawde
Telephone number:	+91-9923757332

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.

The Panel’s Market Surveillance Unit is available for consultation in relation to the Code’s dealing disclosure requirements on +44 (0)20 7638 0129.

The Code can be viewed on the Panel’s website at ssssssswwww.thetakeoverpanel.org.uk.